Merck KGaA struck a deal worth up to €1 billion to acquire five bispecific immuno-oncology antibodies from F-star Alpha.
Bioverativ is buying True North Therapeutics for an upfront payment of $400 million and up to $425 million in milestones.
Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.
Thermo Fisher Scientific Inc. snapped up North Carolina-based Patheon N.V. in a deal valued at $7.2 billion.
Germany-based Fresenius Kabi, part of Fresenius SE & Co. KGaA, slapped down $4.3 billion to acquire Illinois-based Akorn Inc. and a larger toehold in the United States.
U.S. medical equipment supplier Becton Dickinson and Co. will acquire C. R. Bard Inc. in a $24 billion cash-and-stock deal, adding Bard’s devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said.
Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.
Abbott Laboratories and Alere Inc. have come to an accord. Illinois-based Abbott will acquire Alere for an amount less than the initially agreed upon $5.8 billion.
After weeks of bidding and speculation, German-based Stada Arzneimittel AG accepted a $5.6 billion takeover bid from Bain Capital and Cinven Partners LLP.
Astellas Pharma struck a deal valued at up to $853 million to acquire Belgium-based Ogeda SA, a privately held clinical-stage drug discovery company, and its lead drug candidate fezolinetant.